All sponsors

Qilu Pharmaceutical Co., Ltd.

Clinical trial pipeline · active industry-sponsored Phase 1/2 to Phase 3 trials · updated 2026-11-13
ACTIVE TRIALS75
PHASE 3 / 2-344
RECRUITING28
READOUTS ≤12 MONTHS34
READOUT SLIPPED >6 MO9%

Delay Index: of 33 active trials registered more than a year ago, 3 have moved their primary completion (readout) date by more than 6 months since first registration (median +0.0 months). See all sponsors →

Open Qilu Pharmaceutical Co., Ltd. on the live radar map →
TRIALPHASESTATUSCONDITIONNPRIMARY COMPLETION
QLF31907
NCT06394713
P1/2Not yet recruitingAdvanced Malignant Neoplasm602025-06-15
QLC7401
NCT06750341
P2Not yet recruitingPrimary Hypercholesterolemia or Mixed Hyperlipidemia1562026-06
QLM3004 Concentration 1
NCT06151587
P3RecruitingMyopia7352026-06
QLS31905
NCT06446388
P2Not yet recruitingAdvanced Solid Tumor3602026-06-30
MHB088C for Injection
NCT07102004
P1/2RecruitingAdvanced/Metastatic Solid Tumors5152026-07
GM1
NCT06994507
P3RecruitingChemotherapy-induced Peripheral Neuropathy (CIPN)3522026-09
QLC1101+QL1203
NCT06949761
P1/2Not yet recruitingSolid Tumor2402026-09
QLC5508
NCT07256782
P1/2RecruitingAdvanced Solid Tumor4442026-10
QLS31905 for Injection
NCT07151872
P2Not yet recruitingCLDN18.2-positive Advanced Biliary Tract Cancer1202026-10
3-6mg QLM1016
NCT06799559
P3Active, not recruitingSchizophrenia4022026-10-23 (+4 mo)
Relugolix
NCT06671548
P3RecruitingHeavy Menstrual Bleeding; Uterine Fibroids1202026-11-12
Meropenem and Pralurbactam
NCT07089186
P3RecruitingHospital-acquired Bacterial Pneumonia (HABP); Ventilator-associated Bacterial Pneumonia (VABP)802026-12
QL2107
NCT06754644
P3RecruitingNSCLC8082026-12
QL1207H injection
NCT07489586
P3Not yet recruitingNeovascular Age-Related Macular Degeneration (nAMD)3562026-12
QLG1091
NCT07487103
P3Not yet recruitingType 2 Diabetes4782026-12
QLC5508
NCT07198633
P1/2RecruitingAdvanced Prostate Cancer2122026-12
Dose 1 of QLS1410
NCT07489612
P2Enrolling by invitationHypertension (HTN)2602026-12
QLS31905 for Injection
NCT06942767
P2Not yet recruitingGastric Adenocarcinoma; Gastroesophageal Junction Adenocarcinoma1002026-12
QL2107
NCT07162883
P3Active, not recruitingCarcinoma, Non-Small-Cell Lung1462026-12-31
QL1206
NCT07062978
P3RecruitingPostmenopausal Women With Osteoporosis at High Risk of Fracture2782027-01
QLC1401
NCT07173556
P1/2Not yet recruitingAdvanced Breast Cancer962027-02
1.5% QLM3003 ointment
NCT06880276
P3RecruitingAtopic Dermatitis3602027-03
QLS5132; Bevacizumab
NCT07453394
P1/2Not yet recruitingGastric Cancer (GC); Non-small Cell Lung Cancer (NSCLC)6262027-04
QLS1410
NCT07550465
P2Not yet recruitingPrimary Aldosteronism602027-04
QL0911
NCT06456528
P2/3RecruitingCancer Treatment-Induced Thrombocytopenia2352027-04-30 (+10 mo)
Daprodustat
NCT07300111
P3Not yet recruitingAnaemia1002027-05
MHB088C for Injection
NCT06954246
P3RecruitingSmall Cell Lung Cancer Extensive Stage4502027-05
QLG2128
NCT06898060
P3Not yet recruitingPostmenopausal Women With Osteoporosis2822027-05
QL2108 injection
NCT06884891
P3Not yet recruitingAtopic Dermatitis5202027-05
Meropenem and Pralurbactam
NCT06633718
P3Not yet recruitingIntra-abdominal Infections7862027-05-30
ESG401
NCT06732323
P3RecruitingTriple-Negative Breast Cancer (TNBC)5042027-06
QLC5513 IV infusion
NCT07272590
P1/2Not yet recruitingMetastatic Solid Tumors2902027-06
QL2401 25 mg
NCT07620366
P2Not yet recruitingMetabolic Dysfunction-associated Steatohepatitis (MASH)1322027-06
Voclosporin(QL1074)
NCT06406205
P3RecruitingLupus Nephritis2702027-06
QLS12010
NCT07417917
P2Not yet recruitingAdults With Moderate-to-severe Hidradenitis Suppurativa1022027-06-01
Albipagrastim alf
NCT07724756
P2RecruitingPediatric Malignant Solid Tumor; Febrile Neutropenia (FN)182027-06-26
ESG401
NCT06383767
P3RecruitingMetastatic Breast Cancer3782027-06-30 (+11 mo)
QLS5133
NCT07061639
P1/2Not yet recruitingAdvanced Solid Tumors2122027-07
QL1706 injection
NCT05487391
P3RecruitingCarcinoma, Non-Small-Cell Lung6322027-08-31
QLS12010
NCT07344051
P2Not yet recruitingModerate-to-severe Atopic Dermatitis1602027-09
QL1706
NCT05976568
P2/3Not yet recruitingHepatocellular Carcinoma6682027-09-01
QLH12016
NCT07104110
P1/2Not yet recruitingProstatic Neoplasms502027-10
QLC7401
NCT07444086
P3Not yet recruitingPrimary Hypercholesterolemia or Mixed Hyperlipidemia5102027-10-07
QLS32015
NCT07018050
P2RecruitingRelapsed or Refractory Multiple Myeloma1602027-11
QLS5133; Lenvatinib mesylate
NCT07933419
P1/2Not yet recruitingClear Cell Renal Cell Carcinoma; Ovarian Cancer5582027-11-15
QLP2117
NCT06911827
P1/2RecruitingAdvanced Solid Tumor1492027-12
QLC7401
NCT07441317
P3Not yet recruitingPrimary Hypercholesterolemia or Mixed Hyperlipidemia7802027-12
Dose 1 of QLS1410
NCT07927556
P2Not yet recruitingUncontrolled Hypertension2602027-12
QL2109
NCT06742138
P3Not yet recruitingMultiple Myeloma2842027-12
QLS32015
NCT07138209
P3RecruitingRelapsed or Refractory Multiple Myeloma2282027-12
QL0911
NCT07455006
P3Not yet recruitingThrombocytopenia, Immune602027-12-10
QL2106 injection
NCT07511647
P3Active, not recruitingPlaque Psoriasis3182027-12-30
Iparomlimab and Tuvonralimab (QL1706)
NCT06789796
P3Not yet recruitingSmall-cell Lung Cancer6362028-03
GM1
NCT07585565
P2Not yet recruitingParkinson's Disease2762028-03
QLS12010
NCT07377773
P2Not yet recruitingRheumatoid Arthritis (RA)1802028-03-05
QLC7401 Injection
NCT07450378
P3Not yet recruitingHeterozygous Familial Hypercholesterolemia (HeFH)1202028-04
QLS4131
NCT07560449
P2Not yet recruitingMalignant Plasma Cell Neoplasms1622028-06
Meropenem and Pralurbactam
NCT07327619
P3RecruitingHospital-acquired Bacterial Pneumonia and Ventilator-associated Bacterial Pneumonia4202028-06
QLC5508
NCT07463573
P3RecruitingEsophageal Squamous Cell Carcinoma (ESCC)4662028-06-05
QLC5508
NCT07632690
P3Not yet recruitingProstate Cancer7002028-06-20
QL1706
NCT07025239
P3Not yet recruitingMetastatic Colorectal Cancer4302028-07
QLS7305 Injection
NCT07730632
P2Not yet recruitingIgAN - IgA Nephropathy; Immune Complex Membranoproliferative Glomerulonephritis (IC-MPGN)602028-08-10
QLS31905
NCT07716449
P3RecruitingGastric or Gastroesophageal Junction Adenocarcinoma5602028-09
QLS2319
NCT07735104
P1/2RecruitingCancer Cachexia; Cancer Cachexia Syndrome882028-10-30
QLS1304 tablet+Fulvestrant or QLC1401
NCT07235176
P1/2RecruitingAdvanced ER+/HER2- Breast Cancer3002028-11-02
QLS31905
NCT07079228
P3RecruitingPancreatic Cancer6022028-12
tezepelumab (Arm1&Arm2)
NCT07302516
P3Not yet recruitingAsthma6362028-12
QLC5508
NCT07802821
P3RecruitingExtensive-stage Small Cell Lung Cancer5562029-03-15
Investigator's Choice Chemotherapy (FOLFIRI or FOLFOX regimen)
NCT07894211
P3Not yet recruitingExtrapulmonary Neuroendocrine Carcinoma2702029-03-26
QL1706
NCT05690945
P3Active, not recruitingLung Cancer6062029-06 (+47 mo)
Romiplostim N01
NCT07345000
P3Not yet recruitingTreatment-naïve Severe Aplastic Anemia2102029-10
QLS5132
NCT07926048
P3Not yet recruitingEpithelial Ovarian Cancer; Fallopian Tube Cancer4202029-12
QLS4131
NCT07933432
P3Not yet recruitingRelapsed or Refractory Multiple Myeloma3002029-12-14
Iparomlimab and Tuvonralimab (QL1706)Injection
NCT06852456
P2Not yet recruitingResectable Locally Advanced Esophageal Squamous Cell Carcinoma302030-12
QL1706
NCT06686576
P3RecruitingColon Cancer3632030-12